Meeting
2013 ASCO Annual Meeting
Phase I dose escalation study of the protein kinase C iota inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
Authors
Aaron Scott Mansfield
Mayo Clinic, Rochester, MN
Aaron Scott Mansfield , Alan P. Fields , Aminah Jatoi , Yingwei Qi , Alex A. Adjei , Charles Erlichman , Julian R. Molina
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT00575393
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2551)
DOI
10.1200/jco.2013.31.15_suppl.2551
Abstract #
2551
Poster Bd #
3C
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2022 ASCO Annual Meeting
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
First Author: Qing Zhou
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2020 ASCO Virtual Scientific Program
Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
First Author: Mikhail Fedyanin